The Active Pharmaceutical Ingredient (API) Spring 2012 has created the foundation for stronger global partnerships through the Global Buyers Port (GBP) and Sino India Partnership Programme (SIPP). The event, being held at Hefei Binhu International Exhibition Centre, has over 30 companies signing up for the SIPP and GBP. The companies from India are Suven Lifesciences, Anantco, Eastern Chemicals, Agarwals Chemicals Mac Chem Products India, Sheetal Pharma and Vardhman Chemicals.
Some of these companies like Anantco and Eastern Chemicals have a liaison office in China. There is need to source a range of pharma chemicals and excipients. In an age of changing global order where the focus is on chronic diseases and critical disorders to address not just a growing young population but an ageing one too, said representatives of companies from India.
SIPP enables India and China a green channel to work closer and have a better understanding of the requirements and the challenges in conducting businesses. The dialogues with prospective customers can help us comprehend the market, they added.
In fact the Indian Buyers Port (IBP) has brought the global pharma to close proximity for business. “With the success of the IBP which took off in API China Spring 2009, Reed Sinopharm in its effort to bring more strategic and commercial value for its participants organised the GBP. There is a significant representation from Asian markets, Brazil, Europe and US. Companies like IndSwift Labs from India to Uni Chemie International, and Shah Trading Co were looking for business expansions.
“We are looking to widen relations with not just local players but those in the developed world too. The global economic slowdown is providing business opportunities for India and China and we need to see how if collaborations with drug majors of China will work to jointly tap the subdued developed economies, said a participating official.
The action plan for the next two days would be market assessment, look at sourcing potential, bulk import of APIs, sourcing support to the large and growing pharma contract research and manufacture service (CRAMS). In addition, we are also hoping to lay our hands on in-licensing, develop co-market, product development strategies and look at better delivery timeline schedules, said GBP participants.
The future of global pharma industry would only create increased demand for APIs, speciality chemicals, fine chemicals, sterile injectibles and lyophilised products, inhalers, transdermals, suppositories and vaccines, said the participants.